Encoded Therapeutics closed a $275 million Series F round to advance its Dravet syndrome genetic medicine program and to scale its internal manufacturing capabilities. The precision genetic medicine biotech said the financing was led by GV with an additional undisclosed healthcare investor. The round highlights continued institutional confidence in repeatable platforms for delivering targeted therapy in early childhood epilepsies, where durability, safety and production consistency are major commercialization hurdles. Encoded also signaled that manufacturing scale-up is a central driver of the investment, aligning with broader industry pressure to reduce bottlenecks in gene therapy supply chains.